Temasek-backed Transcenta mulls HK-China dual IPO listing

After announcing a $100 million Series B+ funding, the biotech company’s CEO tells FinanceAsia it is now in full IPO preparation mode with Hong Kong as its preferred destination. However, a dual listing is not out of the question.
January 12, 2020

A Chinese Renaissance

Delisting stock and privatising is a big undertaking, but Chinese companies are increasingly using this method to both restructure and recapitalise their businesses. With the right financial partner, it can be a great opportunity to revitalise your brand.

How HK's emergency law may further worry investors

The masks ban using colonial-era legislation further damages Hong Kong's democratic credentials. With no end to the turmoil in sight, the city's financial status continues to weaken.
October 08, 2019

Li & Fung perpetual defies crowded market

The Hong Kong-listed supply chain manager prints an upsized $650 million perpetual non-call five bond, after attracting more than $4.4 billion of orders.
October 28, 2016

MTR keeps Asian green bond surge on track

Asia’s green bond market is growing at breakneck pace, attracting increasing numbers of issuers. After the success of a deal from Hong Kong’s MTR Corp this week, it is not hard to see why.
October 25, 2016

Konruns Pharma's IPO plan aligned with policy

In line with Beijing's push for domestic innovation, the pharmaceutical firm aims to quintuple its product portfolio through in-house R&D and strategic acquisitions.
August 25, 2015

Greenland debuts Asia’s largest Reg-S high-yield bond

The builder of one of China’s tallest buildings has sold a $700 million bond – the largest for a first-time borrower in the sub-investment grade space – underscoring strong appetite for deal structures with extra investor protection.
October 11, 2013